Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.

2021-03

Gleeson, Mary

Counsell, Nicholas

Cunningham, David

Lawrie, Anthony

Clifton-Hadley, Laura

Hawkes, Eliza A

McMillan, Andrew

Ardeshna, Kirit M

Burton, Cathy

Chadwick, Nick

Gambell, Joanna

Smith, Paul

Mouncey, Paul

Pocock, Christopher

Radford, John

Davies, John

Turner, Deborah

Kruger, Anton

Johnson, Peter

Linch, David

clinical trials

diffuse large B-cell lymphoma

international prognostic index

rituximab

Journal Article

0000-0001-6915-9878

0000-0002-9988-5528

0000-0002-0376-2559

10.1111/bjh.16691

We compared the International Prognostic Index (IPI), Revised (R)-IPI and age-adjusted (aa)-IPI as prognostic indices for patients with diffuse large B-cell lymphoma (DLBCL) in the UK National Cancer Research Institute (NCRI) R-CHOP 14 versus 21 trial (N = 1080). The R-IPI and aa-IPI showed no marked improvement compared to the IPI for overall and progression-free survival, in terms of model fit or discrimination. Similar results were observed in exploratory analyses incorporating the Grupo Español de Linfomas/Transplante de Médula Ósea (GELTAMO)-IPI, where baseline β2-microglobulin data were available (N = 655). Although our findings support current use of the IPI, a novel prognostic tool to better delineate a high-risk DLBCL group in the rituximab era is needed.

link

British Journal of Haematology 2021; 192(6): 1015-1019

British Journal of Haematology